SomaLogic founder, CTO among shareholders opposing Standard BioTools merger

BOULDER — Among the growing list of stakeholders who oppose SomaLogic Inc.’s (Nasdaq: SLGC) planned $1 billion merger with California-based Standard BioTools Inc. (Nasdaq: LAB) are the biotechnology firm’s founder and its chief technology officer.

Larry Gold, who founded SomaLogic in 2000 and was previously the firm’s CEO, and Jason Cleveland, its CTO since 2021, recently penned an open letter asking shareholders to join their opposition. 

“Both of us have great faith in SomaLogic’s potential,” the pair wrote. “Both of us also have serious concerns about the proposed stock-for-stock combination between the company and Standard BioTools Inc.

The merger…